D-0270-2025 Class II Ongoing
FDA drug recall D-0270-2025 was initiated by Breckenridge Pharmaceutical, Inc. on Feb 28, 2025 and is designated Class II. Reason for recall: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit. The recall status is ongoing. Affected quantity: 14,749 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Mar 19, 2025
- Initiation Date
- Feb 28, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 14,749 bottles.
Product description
Duloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, 1000-count bottles, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. NDC 51991-747-10
Reason for recall
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
Distribution pattern
Nationwide
Code information
Lot#: 240225C, Expiration: 01/2027
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0270-2025
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026